COCH - Envoy Medical, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

COCH

ENVOY MEDICAL, INC.

NASDAQ

$0.66

▲ UP 0.64% (0.00)

KEY STATISTICS

Market Cap$50.18 M

52w High$1.02

52w Low$0.36

Dividend Yield—

Frequency—

P/E-0.83

Volume30.67K

Shares Out.77.19M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Brent T. Lucas

ABOUT

SECTOR

Healthcare

WENT PUBLIC

April 29, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$2.00

Target Low$2.00

Target Median$2.00

Target Consensus$2.00

UPCOMING EARNINGS

DateNov 9, 2026

DayMonday

Rev. Est.$66.67K

NOV

MON

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

VXF

0.00%

606.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED

21.55%

HOLDERS

TOP 8 OF 52 · RANKED BY POSITION SIZE

Nantahala Capital Management, LLC

Dsg Capital Advisors, LLC

625.0K sh

$415.69K

Atlas Merchant Capital LLC

555.5K sh

$430.92K

Geode Capital Management, LLC

Weiss Asset Management LP

242.6K sh

$188.22K

PRICE

$0.66 ▲ UP 0.64% (+$0.00)

About Envoy Medical, Inc.

https://www.envoymedical.com ↗

Envoy Medical, founded in 1995 and based in Minnesota, offers hearing loss solutions including hearing aids, middle ear implants, bone conduction devices, and cochlear implants.

INDUSTRY

Medical - Devices

A PRODUCT ENVOY MEDICAL, INC. IS KNOWN FOR

Acclaim® Cochlear Implant

The Acclaim® Cochlear Implant is a fully implanted device for adults with severe to profound hearing loss, using natural ear anatomy to capture sound, currently in final clinical trials for FDA approval.

Envoy Medical in 2025

SENTIMENT: + POSITIVE

REGULATORY · OCTOBER 7, 2025

Envoy Medical Receives FDA Approval to Expand Pivotal Clinical Trial for Its Fully Implanted Acclaim® Cochlear Implant

Envoy Medical announced it received approval from the U.S. Food and Drug Administration (FDA) to expand the pivotal clinical trial for its fully implanted Acclaim® cochlear implant to its final stage. This decision followed promising three-month data from the initial ten trial participants and was viewed as a significant de-risking event, removing a key timing uncertainty for the company. The approval allowed Envoy to accelerate its expected commercialization timeline by three to six months and reduce its anticipated capital needs by $10–$15 million.

CAPITAL ALLOCATION · AUGUST 2025 · COMPLETED

Envoy Medical Executes Transformational Debt Restructuring, Eliminating $32 Million in Debt to Fund Pivotal Acclaim® Cochlear Implant Trial

In a pivotal strategic move to solidify its financial foundation, Envoy Medical extinguished over $32 million in debt for a cash payment of just $100,000. This significant deleveraging was a deliberate decision to strengthen the company's balance sheet, reduce financial risk, and secure the necessary capital to advance its lead product, the investigational Acclaim® fully implanted cochlear implant, through its final clinical trial stage.